Health Condition 1: null- Chronic Proteinuric Nephropathy
Conditions
Interventions
Intervention1: Calcitriol and Enalapril: Calcitriol 0.25-0.5 microgram twice weekly,Enalapril 0.5mgper Kg per day ,for 6 months
Control Intervention1: Enalapril.
: Enalapril 0.5 mg per Kg per day fo
Sponsors
ICMR
Eligibility
Inclusion criteria
Inclusion criteria: 1.Normal blood pressure on stable doses of antihypertensive drugs for 1 month 2.Estimated GFR 30 -90 ml/min/1.73 m2 3.Children on corticosteroid should be on stable doses of corticosteroids for last 2 month
Exclusion criteria
Exclusion criteria: Following children will be excluded from the study. 1.Patients below 3 years of age 2.Patients with estimated GFR 30 ml/min/1.73m2 3.Patients with chronic liver disease or deranged transaminase levels (more than 2 times the normal) 4.Patients with phosphorus levels 5.5 mg/dl, current hypercalcemia (serum calcium 10.5 mg/dl) or untreated primary hyperparathyroidism. 5.Patients with hypercalciuria (24 h urinary calcium 4 mg/kg/d) 6.Children residing outside 200km of the Delhi border. 7.History of nephrolithiasis. 8.Known malabsorption syndromes, e.g., celiac disease, active inflammatory bowel disease, etc. 9.Treatment with vitamin D or any of its active metabolites in last 4 weeks 10.Treatment with any drug which may interfere with vitamin D metabolism, e.g., phenobarbital, phenytoin. 11.Patients with bilateral renal artery stenosis. 12.Patients on immunosuppressive drugs such as cyclophosphamide, calcineurin inhibitors, azathioprine 13.Steroid responsive nephrotic syndrome 14.Patients on high dose (2 mg/kg/d prednisolone or equivalent) or intravenous corticosteroids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Degree of ProteinuriaTimepoint: at 0 and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| intact parathormone, 25OH vitamin D, highly selective C reactive protein, estimated Glomerular filtration rate, Carotid intimal medial thickness, Flow mediated dilatation of brachial artery, Occurence of hypercalcemia hyperposphatemiaTimepoint: at 0 and 6 months | — |
Countries
India
Contacts
Public ContactDrPankaj Hari
AIIMS
Outcome results
None listed